
TRAX Stock Forecast & Price Target
TRAX Analyst Ratings
Bulls say
First Tracks is expected to see future success with its strong pipeline and targeted and well-researched treatment options for various autoimmune and inflammatory diseases, specifically ANB033. The company's sound financials and ongoing clinical trials, particularly in EoE and other conditions, further support its potential in the market. The FDA's draft guidance and competitive landscape are also favorable indicators for First Tracks' success in the long-term.
Bears say
First Tracks is facing multiple challenges that could impact the success of their pipeline drugs. With no approved drugs and potential regulatory changes, the success of their clinical trials may be at risk. Additionally, there are already approved biologics targeting the same pathways as their drugs in development, making it difficult for them to stand out in the market. Lastly, their pipeline drugs face tough competition from currently available treatments and may not be able to differentiate themselves in terms of efficacy and safety.
This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRAX Analyst Forecast & Price Prediction
Start investing in TRAX
Order type
Buy in
Order amount
Est. shares
0 shares